TABATHA TIMBERMAN: Open Payments
NPI 1033780473 · RICHMOND, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$438 in 22 payments from 11 companies in 2025. Trend: 2023 $105 · 2024 $220 · 2025 $438
Food & beverage: $420Education: $17
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. | 7 | $123 |
| GENZYME CORPORATION | 3 | $68 |
| AstraZeneca Pharmaceuticals LP | 2 | $42 |
| Insmed, Inc. | 2 | $39 |
| Viatris Specialty LLC | 2 | $38 |
| Grifols USA, LLC | 1 | $31 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Verona Pharma, Inc. | 1 | $23 |
| Electromed, Inc. | 1 | $15 |
| Amgen Inc. | 1 | $14 |
Products named: DUPIXENT, NUCALA, TRELEGY ELLIPTA, FASENRA, YUPELRI, Prolastin-C Liquid, Ohtuvayre, Arikayce.
Industry payments across IN — which companies pay providers there.
